
TY  - JOUR
TI  - BONE DISEASES OTHER THAN OSTEOPOROSIS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_4.x
DO  - doi:10.1111/j.1479-8077.2006.00199_4.x
SP  - A31
EP  - A33
PY  - 2006
ER  - 

TY  - JOUR
TI  - Abstracts cont.
JO  - Clinical Microbiology and Infection
VL  - 11
IS  - s2
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1469-0691.2005.01135.x
DO  - doi:10.1111/j.1469-0691.2005.01135.x
SP  - 648
EP  - 744
PY  - 2005
ER  - 

TY  - JOUR
TI  - SYSTEMIC LUPUS ERYTHEMATOSUS – AETIOLOGY AND PATHOGENESIS/ANIMAL MODELS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_29.x
DO  - doi:10.1111/j.1479-8077.2006.00199_29.x
SP  - A247
EP  - A253
PY  - 2006
ER  - 

TY  - JOUR
TI  - CARTILAGE IN BONE BIOLOGY AND PATHOPHYSIOLOGY
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_5.x
DO  - doi:10.1111/j.1479-8077.2006.00199_5.x
SP  - A33
EP  - A39
PY  - 2006
ER  - 

TY  - JOUR
AU  - Daigo, Kenji
AU  - Inforzato, Antonio
AU  - Barajon, Isabella
AU  - Garlanda, Cecilia
AU  - Bottazzi, Barbara
AU  - Meri, Seppo
AU  - Mantovani, Alberto
TI  - Pentraxins in the activation and regulation of innate immunity
JO  - Immunological Reviews
JA  - Immunol Rev
VL  - 274
IS  - 1
SN  - 0105-2896
UR  - https://doi.org/10.1111/imr.12476
DO  - doi:10.1111/imr.12476
SP  - 202
EP  - 217
KW  - cancer-related inflammation
KW  - complement activation
KW  - inflammation
KW  - opsonization
KW  - pentraxins
KW  - PTX3
PY  - 2016
AB  - Summary Humoral fluid phase pattern recognition molecules (PRMs) are a key component of the activation and regulation of innate immunity. Humoral PRMs are diverse. We focused on the long pentraxin PTX3 as a paradigmatic example of fluid phase PRMs. PTX3 acts as a functional ancestor of antibodies and plays a non-redundant role in resistance against selected microbes in mouse and man and in the regulation of inflammation. This molecule interacts with complement components, thus modulating complement activation. In particular, PTX3 regulates complement-driven macrophage-mediated tumor progression, acting as an extrinsic oncosuppressor in preclinical models and selected human tumors. Evidence collected over the years suggests that PTX3 is a biomarker and potential therapeutic agent in humans, and pave the way to translation of this molecule into the clinic.
ER  - 

TY  - JOUR
TI  - Posters
JO  - European Journal of Clinical Investigation
JA  - Eur J Clin Invest
VL  - 49
IS  - S1
SN  - 0014-2972
UR  - https://doi.org/10.1111/eci.13109
DO  - doi:10.1111/eci.13109
SP  - 101
EP  - 221
PY  - 2019
ER  - 

AU  - Bekwelem, Wobo
AU  - Hirsch, Alan T.
C7  - pp. 1-35
TI  - Epidemiology of Peripheral Artery Disease
SN  - 9781118776094
UR  - https://doi.org/10.1002/9781118775998.ch1
DO  - doi:10.1002/9781118775998.ch1
SP  - 1-35
KW  - acute limb ischemia
KW  - atypical leg pain
KW  - classic claudication
KW  - critical limb ischemia
KW  - peripheral artery disease syndromes
PY  - 2019
AB  - Summary This chapter describes the epidemiology of peripheral artery disease (PAD), and discusses the definitions used to describe PAD and PAD syndromes. It then summarizes the prevalence and incidence, risk factors, progression and outcomes of PAD. Peripheral artery disorders include atherosclerosis, plaque rupture, abnormal vascular reactivity, vasospasm, inflammation, arterial wall dysplasia, and thrombus formation leading to occlusion. There are five recognized clinical syndromes of PAD that are characterized by distinct presentations. These syndromes are useful both in describing the epidemiology of PAD and in clinical care. They include: asymptomatic PAD, classic claudication, atypical leg pain, acute limb ischemia (ALI) and critical limb ischemia (CLI). PAD incidence and prevalence rates are similar in high- and low- to middle-income countries. PAD is as much a problem in high-income countries (HICs) as it is in low- to medium-income countries (LMICs). Finally, the chapter highlights the low awareness of PAD in the community.
ER  - 

TY  - JOUR
TI  - Danish Association for Cancer Research Annual meeting 2006
JO  - APMIS
VL  - 114
IS  - 3
SN  - 9781118776094
UR  - https://doi.org/10.1111/j.1600-0463.2006..x
DO  - doi:10.1111/j.1600-0463.2006..x
SP  - 163
EP  - 191
PY  - 2006
ER  - 

TY  - JOUR
TI  - Paper Abstracts
JO  - Journal of the American Geriatrics Society
VL  - 51
IS  - s4
SN  - 9781118776094
UR  - https://doi.org/10.1034/j.1600-0889.2000.00001.x
DO  - doi:10.1034/j.1600-0889.2000.00001.x
SP  - 27
EP  - 237
PY  - 2003
ER  - 

TY  - JOUR
TI  - Free Communications: Lymphoproliferative Disorders
JO  - British Journal of Haematology
VL  - 137
IS  - s1
SN  - 9781118776094
UR  - https://doi.org/10.1111/j.1365-2141.2007.06557.x
DO  - doi:10.1111/j.1365-2141.2007.06557.x
SP  - 1
EP  - 88
PY  - 2007
ER  - 

TY  - JOUR
TI  - Abstracts of The Annual Meeting
JO  - Hepatology
JA  - Hepatology
VL  - 5
IS  - 5
SN  - 9781118776094
UR  - https://doi.org/10.1002/hep.1840050545
DO  - doi:10.1002/hep.1840050545
SP  - 947
EP  - 1063
PY  - 1985
ER  - 

TY  - JOUR
TI  - ACR/ARHP scientific abstracts
JO  - Arthritis & Rheumatism
JA  - Arthritis & Rheumatism
VL  - 42
IS  - S9
SN  - 9781118776094
UR  - https://doi.org/10.1002/art.1780422107
DO  - doi:10.1002/art.1780422107
SP  - S71
EP  - S407
PY  - 1999
ER  - 

TY  - JOUR
TI  - Poster abstracts
JO  - Vox Sanguinis
VL  - 93
IS  - s1
SN  - 9781118776094
UR  - https://doi.org/10.1111/j.1423-0410.2007.00932.x
DO  - doi:10.1111/j.1423-0410.2007.00932.x
SP  - 54
EP  - 274
PY  - 2007
ER  - 

TY  - JOUR
TI  - Workshops
JO  - European Journal of Clinical Investigation
JA  - Eur J Clin Invest
VL  - 44
IS  - s1
SN  - 9781118776094
UR  - https://doi.org/10.1111/eci.12258
DO  - doi:10.1111/eci.12258
SP  - 4
EP  - 82
PY  - 2014
ER  - 

TY  - JOUR
TI  - 2012 ACVIM Forum Research Abstracts Program
JO  - Journal of Veterinary Internal Medicine
JA  - J Vet Intern Med
VL  - 26
IS  - 3
SN  - 9781118776094
UR  - https://doi.org/10.1111/j.1939-1676.2012.00937.x
DO  - doi:10.1111/j.1939-1676.2012.00937.x
SP  - 690
EP  - 822
PY  - 2012
ER  - 

TY  - JOUR
TI  - Oral Abstracts
JO  - Medical Education
JA  - Med Educ
VL  - 51
IS  - S1
SN  - 9781118776094
UR  - https://doi.org/10.1111/medu.13284
DO  - doi:10.1111/medu.13284
SP  - 22
EP  - 117
PY  - 2017
ER  - 

TY  - JOUR
TI  - Australasian College of Dermatologists Abstracts Presented at the 52nd Annual Scientific Meeting 18–21 May 2019 Melbourne Convention and Exhibition Centre Melbourne, Victoria
JO  - Australasian Journal of Dermatology
JA  - Australas J Dermatol
VL  - 60
IS  - S1
SN  - 9781118776094
UR  - https://doi.org/10.1111/ajd.13027
DO  - doi:10.1111/ajd.13027
SP  - 14
EP  - 106
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of Neurochemistry
VL  - 109
IS  - s1
SN  - 9781118776094
UR  - https://doi.org/10.1111/j.1471-4159.2009.05927.x
DO  - doi:10.1111/j.1471-4159.2009.05927.x
SP  - 265
EP  - 313
PY  - 2009
ER  - 

AU  - Attal, N.
AU  - Cruccu, G.
AU  - Baron, R.
AU  - Haanpää, M.
AU  - Hansson, P.
AU  - Jensen, T. S.
AU  - Nurmikko, T.
C7  - pp. 399-410
TI  - Treatment of Neuropathic Pain
SN  - 9781405185332
UR  - https://doi.org/10.1002/9781444328394.ch26
DO  - doi:10.1002/9781444328394.ch26
SP  - 399-410
KW  - neurological problems - neuropathic pain treatment
KW  - neuropathic pain (NP), causing lesion or disease of somatosensory system
KW  - European Federation of Neurological Societies (EFNS) - first guidelines on pharmacological treatment of NP
KW  - efficacy of tricyclic antidepressants (TCAs) - established in PPN (notably diabetic), based on single-centre Vlass I or II trials
KW  - postherpetic neuralgia (PHN), common aftermath of herpes zoster in the elderly
KW  - symptomatic TN - only small open-label Class IV studies - in symptomatic TN associated with multiple sclerosis
KW  - classification of evidence for drug treatments - in less commonly studied NP conditions
KW  - effects on pain symptoms and signs and predictors of response
KW  - effects on quality of life, sleep and mood
KW  - multi-aetiology NP, positive mainly for TCAs, opioids and cannabinoids
PY  - 2009
AB  - Summary This chapter contains sections titled: Background and objectives Methods Results References
ER  - 

TY  - JOUR
AU  - Hawiger, J.
AU  - Veach, R. A.
AU  - Zienkiewicz, J.
TI  - New paradigms in sepsis: from prevention to protection of failing microcirculation
JO  - Journal of Thrombosis and Haemostasis
JA  - J Thromb Haemost
VL  - 13
IS  - 10
SN  - 9781405185332
UR  - https://doi.org/10.1111/jth.13061
DO  - doi:10.1111/jth.13061
SP  - 1743
EP  - 1756
KW  - genome
KW  - infection
KW  - inflammation
KW  - microcirculation
KW  - septic shock
PY  - 2015
AB  - Summary Sepsis, also known as septicemia, is one of the 10 leading causes of death worldwide. The rising tide of sepsis due to bacterial, fungal and viral infections cannot be stemmed by current antimicrobial therapies and supportive measures. New paradigms for the mechanism and resolution of sepsis and consequences for sepsis survivors are emerging. Consistent with Benjamin Franklin's dictum ?an ounce of prevention is worth a pound of cure?, sepsis can be prevented by vaccinations against pneumococci and meningococci. Recently, the NIH NHLBI Panel redefined sepsis as ?severe endothelial dysfunction syndrome in response to intravascular and extravascular infections causing reversible or irreversible injury to the microcirculation responsible for multiple organ failure?. Microvascular endothelial injury underlies sepsis-associated hypotension, edema, disseminated intravascular coagulation, acute respiratory distress syndrome and acute kidney injury. Microbial genome products trigger ?genome wars? in sepsis that reprogram the human genome and culminate in a ?genomic storm? in blood and vascular cells. Sepsis can be averted experimentally by endothelial cytoprotection through targeting nuclear signaling that mediates inflammation and deranged metabolism. Endothelial ?rheostats? (e.g. inhibitors of NF-?B, A20 protein, CRADD/RAIDD protein and microRNAs) regulate endothelial signaling. Physiologic ?extinguishers? (e.g. suppressor of cytokine signaling 3) can be replenished through intracellular protein therapy. Lipid mediators (e.g. resolvin D1) hasten sepsis resolution. As sepsis cases rose from 387 330 in 1996 to 1.1 million in 2011, and are estimated to reach 2 million by 2020 in the US, mortality due to sepsis approaches that of heart attacks and exceeds deaths from stroke. More preventive vaccines and therapeutic measures are urgently needed.
ER  - 
